The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 12, 2013, Pages 1541-1554

  Tralau, Tewes ^a   Luch, Andreas ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

AHR; CYP evolution; CYP CYP interaction; CYPs; Cytochrome P450; Endo xenobiotic metabolism; ER; Molecular interaction; Regulation; Regulatory crosstalk; Regulatory network

Indexed keywords

ALKANE; ALKENE; AROMATASE; BARBITURIC ACID DERIVATIVE; BENZOIC ACID DERIVATIVE; CELL NUCLEUS RECEPTOR; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B4; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCOCORTICOID; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HETERODIMER; PENTACHLOROPHENOL; POLYCYCLIC AROMATIC HYDROCARBON; RETINOID X RECEPTOR; STEROID 21 MONOOXYGENASE; TRICLOCARBAN; UNSPECIFIC MONOOXYGENASE; VITAMIN D; XENOBIOTIC AGENT;

ARABIDOPSIS THALIANA; ASPERGILLUS FUMIGATUS; BACILLUS MEGATERIUM; CARBON SOURCE; CHEMOPROPHYLAXIS; CHOLESTEROL SYNTHESIS; CONFORMATIONAL TRANSITION; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG METABOLISM; ENHANCER REGION; FATTY ACID METABOLISM; GENE CONTROL; HUMAN; LIPOGENESIS; MEMBRANE STRUCTURE; NONHUMAN; OLIGOMERIZATION; PLASTICITY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STEROID METABOLISM; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; OXIDATION-REDUCTION; PROTEIN CONFORMATION; XENOBIOTICS;

EID: 84888127300     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.828692     Document Type: Review

References (135)

1. Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophys 1958;75(2):376-86
2. Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237(4):PC1375-PC76
3. Munro AW, Girvan HM, McLean KJ. Variations on a (t)heme-novel mechanisms, redox partners and catalytic functions in the cytochrome P450 superfamily. Nat Prod Rep 2007;24(3):585
4. Guengerich FP, Tang Z, Cheng Q, et al. Approaches to deorphanization of human and microbial cytochrome P450 enzymes. Biochim Biophys Acta 2011;1814(1):139-45
5. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6(12):947-60
6. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006;34(5):880-6
7. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 2004;34(7):633-64
8. Nelson DR. Progress in tracing the evolutionary paths of cytochrome P450. Biochim Biophys Acta 2011;1814(1):14-18
9. Nelson DR, Goldstone JV, Stegeman JJ. The cytochrome P450 genesis locus: the origin and evolution of animal cytochrome P450s. Philos Trans R Soc Lond: B Biol Sci 2013;368(1612):20120474
10. Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol 2000;1(6):1-9
11. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999;369(1):1-10
12. Gotoh O. Evolution of cytochrome p450 genes from the viewpoint of genome informatics. Biol Pharm Bull 2012;35(6):812-17
13. Markov GV, Tavares R, Dauphin-Villemant C, et al. Independent elaboration of steroid hormone signaling pathways in metazoans. Proc Natl Acad Sci USA 2009;106(29):11913-18
14. Foti RS, Honaker M, Nath A, et al. Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function. Biochemistry 2011;50(13):2387-93
15. Thomas JH. Rapid birth-death evolution specific to xenobiotic cytochrome P450 genes in vertebrates. PLoS Genet 2007;3(5):e67
16. Denisov IG, Makris TM, Sligar SG, et al. Structure and chemistry of cytochrome P450. Chem Rev 2005;105(6):2253-77
17. Munro AW, Lindsay JG. Bacterial cytochromes P-450. Mol Microbiol 1996;20(6):1115-25
18. Nagy I, Compernolle F, Ghys K, et al. A single cytochrome P-450 system is involved in degradation of the herbicides EPTC (S-ethyl dipropylthiocarbamate) and atrazine by Rhodococcus sp. strain NI86/21. Appl Environ Microbiol 1995;61(5):2056-60
19. Hudson SA, McLean KJ, Munro AW, et al. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets. Biochem Soc Trans 2012;40(3):573-9
20. McLean KJ, Clift D, Lewis DG, et al. The preponderance of P450s in the Mycobacterium tuberculosis genome. Trends Microbiol 2006;14(5):220-8
21. McLean KJ, Munro AW. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis. Drug Metab Rev 2008;40(3):427-46
22. Stewart GR, Wernisch L, Stabler R, et al. Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays. Microbiology 2002;148(10):3129-38
23. Driscoll MD, McLean KJ, Cheesman MR, et al. Expression and characterization of Mycobacterium tuberculosis CYP144: Common themes and lessons learned in the M. tuberculosis P450 enzyme family. Biochim Biophys Acta 2011;1814(1):76-87
24. Ning D, Wang H. Involvement of cytochrome P450 in pentachlorophenol transformation in a white rot fungus Phanerochaete chrysosporium. PLoS ONE 2012;7(9):e45887
25. Ichinose H. Molecular and functional diversity of fungal cytochrome P450s. Biol Pharm Bull 2012;35(6):833-7
26. Črešnar B, Petrič Š. Cytochrome P450 enzymes in the fungal kingdom. Biochim Biophys Acta 2011;1814(1):29-35
27. Perrin RM, Fedorova ND, Bok JW, et al. Transcriptional regulation of chemical diversity in Aspergillus fumigatus by LaeA. PLoS Pathog 2007;3(4):e50
28. Koo AJK, Cooke TF, Howe GA. Cytochrome P450 CYP94B3 mediates catabolism and inactivation of the plant hormone jasmonoyl-L-isoleucine. Proc Natl Acad Sci USA 2011;108(22):9298-303
29. Nelson D, Werck-Reichhart D. A P450-centric view of plant evolution. Plant J 2011;66(1):194-211
30. Iga M, Kataoka H. Recent studies on insect hormone metabolic pathways mediated by cytochrome P450 enzymes. Biol Pharm Bull 2012;35(6):838-43
31. Ohnishi T, Yokota T, Mizutani M. Insights into the function and evolution of P450s in plant steroid metabolism. Phytochemistry 2009;70(17-18):1918-29
32. Qi X, Bakht S, Qin B, et al. A different function for a member of an ancient and highly conserved cytochrome P450 family: from essential sterols to plant defense. Proc Natl Acad Sci USA 2006;103(49):18848-53
33. Field B, Osbourn AE. Metabolic diversification-independent assembly of operon-like gene clusters in different plants. Science 2008;320(5875):543-7
34. Qi X, Bakht S, Leggett M, et al. A gene cluster for secondary metabolism in oat: implications for the evolution of metabolic diversity in plants. Proc Natl Acad Sci USA 2004;101(21):8233-8
35. Mizutani M. Impacts of diversification of cytochrome P450 on plant metabolism. Biol Pharm Bull 2012;35(6):824-32
36. Harrison RM, Hester RE. editors. Chlorinated organic micropollutants. Royal Society of Chemistry; Great Britian: 1995
37. Feyereisen R. Arthropod CYPomes illustrate the tempo and mode in P450 evolution. Biochim Biophys Acta 2011;1814(1):19-28
38. Goldstone JV, McArthur AG, Kubota A, et al. Identification and developmental expression of the full complement of cytochrome P450 genes in Zebrafish. BMC Genomics 2010;11:643
39. Sugimoto H, Shiro Y. Diversity and substrate specificity in the structures of steroidogenic cytochrome P450 enzymes. Biol Pharm Bull 2012;35(6):818-23
40. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28(1):235-42
41. Munro AW, Girvan HM, Mason AE, et al. What makes a P450 tick? Trends Biochem Sci 2013;38(3):140-50
42. McLean KJ, Girvan HM, Munro AW. Cytochrome P450/redox partner fusion enzymes: biotechnological and toxicological prospects. Expert Opin Drug Metab Toxicol 2007;3(6):847-63
43. Rittle J, Green MT. Cytochrome P450 compound I: capture, characterization, and C-H bond activation kinetics. Science 2010;330(6006):933-7
44. Shakunthala N. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome. Expert Opin Drug Metab Toxicol 2010;6(1):1-15
45. Sansen S, Yano JK, Reynald RL, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 2007;282(19):14348-55
46. Denisov IG, Shih AY, Sligar SG. Structural differences between soluble and membrane bound cytochrome P450s. J Biochem 2012;108:150-8
47. Jiang W, Ghosh D. Motion and flexibility in human cytochrome P450 aromatase. PLoS One 2012;7(2):e32565
48. Munro AW, Leys DG, McLean KJ, et al. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem Sci 2002;27(5):250-7
49. Praporski S, Ng SM, Nguyen AD, et al. Organization of cytochrome P450 enzymes involved in sex steroid synthesis: Protein-protein interactions in lipid membranes. J Biol Chem 2009;284(48):33224-32
50. Davydov DR. Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 2011;7(5):543-58
51. Denisov IG, Frank DJ, Sligar SG. Cooperative properties of cytochromes P450. Pharmacol Ther 2009;124(2):151-67
52. Davydov DR, Halpert JR. Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol 2008;4(12):1523-35
53. Idkowiak J, Randell T, Dhir V, et al. A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true isolated 17,20 lyase deficiency. J Clin Endocrinol Metab 2012;97(3):E465-75
54. Hershkovitz E, Parvari R, Wudy SA, et al. Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab 2008;93(9):3584-8
55. Jushchyshyn MI, Hutzler JM, Schrag ML, et al. Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys 2005;438(1):21-8
56. Voice MW, Zhang Y, Wolf CR, et al. Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Arch Biochem Biophys 1999;366(1):116-24
57. Pudney CR, Heyes DJ, Khara B, et al. Kinetic and spectroscopic probes of motions and catalysis in the cytochrome P450 reductase family of enzymes. FEBS J 2012;279(9):1534-44
58. Leferink NG, Pudney CR, Brenner S, et al. Gating mechanisms for biological electron transfer: integrating structure with biophysics reveals the nature of redox control in cytochrome P450 reductase and copper-dependent nitrite reductase. FEBS Lett 2012;586(5):578-84
59. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23(6):1089-116
60. Corcos L, Lucas D, Le Jossic-Corcos C, et al. Human cytochrome P450 4F3: structure, functions, and prospects. Drug Metabol Drug Interact 2012;27(2):63-71
61. Peer CJ, Sissung TM, Figg WD. CHIP and gp78-mediated ubiquitination of CYP3A4: implications for the pharmacology of anticancer agents. Cancer Biol Ther 2011;11(6):549-51
62. Pabarcus MK, Hoe N, Sadeghi S, et al. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys 2009;483(1):66-74
63. Tokizane T, Shiina H, Igawa M, et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 2005;11(16):5793-801
64. Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett 2012;324(1):13-30
65. Jin M, Kumar A, Kumar S. Ethanol-mediated regulation of cytochrome P450 2A6 expression in monocytes: role of oxidative stress-mediated PKC/MEK/Nrf2 pathway. PLoS ONE 2012;7(4):e35505
66. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS Journal 2008;10(2):391-400
67. Lee S, Kim D. Cytochrome P450 networks in chemical space. Arch Pharm Res 2010;33(9):1361-74
68. Goldstone JV, Goldstone HM, Morrison AM, et al. Cytochrome P450 1 genes in early deuterostomes (tunicates and sea urchins) and vertebrates (chicken and frog): origin and diversification of the CYP1 gene family. Mol Biol Evol 2007;24(12):2619-31
69. Kawajiri K, Fujii-Kuriyama Y. Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys 2007;464(2):207-12
70. Mitchell KA, Elferink CJ. Timing is everything: consequences of transient and sustained AhR activity. Biochem Pharmacol 2009;77(6):947-56
71. Jorge-Nebert LF, Jiang Z, Chakraborty R, et al. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 2010;31(1):27-40
72. Ueda R, Iketaki H, Nagata K, et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 2006;69(6):1924-30
73. Zhou H, Qu Y, Wu H, et al. Molecular phylogenies and evolutionary behavior of AhR (aryl hydrocarbon receptor) pathway genes in aquatic animals: implications for the toxicology mechanism of some persistent organic pollutants (POPs). Chemosphere 2010;78(2):193-205
74. Uno T, Ishizuka M, Itakura T. Cytochrome P450 (CYP) in fish. Environ Toxicol Pharmacol 2012;34(1):1-13
75. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009;9:187
76. Braeuning A, Kohle C, Buchmann A, et al. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci 2011;122(1):16-25
77. Ohtake F, Fujii-Kuriyama Y, Kawajiri K, et al. Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J Steroid Biochem Mol Biol 2011;127(1-2):102-7
78. Tsuchiya Y, Nakajima M, Kyo S, et al. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004;64(9):3119-25
79. Rataj F, Moller FJ, Jahne M, et al. Regulation of uterine AHR battery gene expression by 17beta-Estradiol is predominantly mediated by estrogen receptor alpha. Arch Toxicol 2012;86(10):1603-12
80. Tarnow P, Tralau T, Hunecke D, et al. Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells. Toxicol in Vitro 2013;27(5):1467-75
81. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 2008;23(1):14-21
82. Pan Y-Z, Gao W, Yu A-M. MicroRNAs regulate CYP3A4 expression via direct and indirecttargeting. Drug Metab Dispos 2009;37(10):2112-17
83. Jennewein C, von Knethen A, Schmid T, et al. microRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem 2010;285(16):11846-53
84. Karbiener M, Fischer C, Nowitsch S, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARg. Biochem Biophys Res Commun 2009;390(2):247-51
85. Dong H, Lin W, Wu J, et al. Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells. BMC Biochem 2010;11:23-32
86. Munro AW, Girvan HM, McLean KJ. Cytochrome P450-redox partner fusion enzymes. Biochim Biophys Acta 2007;1770(3):345-59
87. Patel JP, Brocks DR. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 2009;5(11):1385-98
88. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011;1814(1):186-99
89. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the "missing heritability" problem. Front Genet 2013;4:12
90. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metabol 2008;9(7):598-610
91. Baker ME. Origin and diversification of steroids: co-evolution of enzymes and nuclear receptors. Mol Cell Endocrinol 2011;334(1-2):14-20
92. Zhu BT. On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin Drug Metab Toxicol 2010;6(4):483-94
93. Bulun SE, Chen D, Moy I, et al. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012;23(2):83-9
94. Schults MA, Timmermans L, Godschalk RW, et al. Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem 2010;285(19):14558-64
95. Tsuchiya Y, Nakajima M, Takagi S, et al. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006;66(18):9090-8
96. Bookout AL, Jeong Y, Downes M, et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;126(4):789-99
97. Stocco C. Tissue physiology and pathology of aromatase. Steroids 2012;77(1-2):27-35
98. Henkler F, Stolpmann K, Luch A. Exposure to polycyclic aromatic hydrocarbons: bulky DNA adducts and cellular responses. EXS 2012;101:107-31
99. Stolpmann K, Brinkmann J, Salzmann S, et al. Activation of the aryl hydrocarbon receptor sensitises human keratinocytes for CD95L-and TRAIL-induced apoptosis. Cell Death Dis 2012;3:e388
100. Rezen T, Rozman D, Pascussi J-M, et al. Interplay between cholesterol and drug metabolism. Biochim Biophys Acta 2011;1814(1):146-60
101. McLean KJ, Hans M, Munro AW. Cholesterol, an essential molecule: diverse roles involving cytochrome P450 enzymes. Biochem Soc Trans 2012;40(3):587-93
102. Lutz JD, Isoherranen N. In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors. Expert Opin Drug Metab Toxicol 2012;8(4):449-66
103. Tralau T. Luch A. "Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology. Expert Opin Drug Metab Toxicol 2012;8(11):1357-62
104. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-41
105. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48(11):689-723
106. Bansal S, Anandatheerthavarada HK, Prabu GK, et al. Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J Biol Chem 2013;288(18):12627- 44
107. Sadee W, Wang D, Papp AC, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther 2011;89(3):355-65
108. Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 2011;26(1):3-14
109. Cali JJ, Ma D, Wood MG, et al. Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates. Expert Opin Drug Metab Toxicol 2012;8(9):1115-30
110. Kumar S. Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation. Expert Opin Drug Metab Toxicol 2010;6(2):115-31
111. Tralau T, Luch A. Drug-mediated toxicity: illuminating the 'bad' in the test tube by means of cellular assays? Trends Pharmacol Sci 2012;33(7):353-64
112. Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 2007;15(15):5047-60
113. Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011;125(1-2):13-22
114. Ghosh D, Lo J, Morton D, et al. Novel aromatase inhibitors by structure-guided design. J Med Chem 2012;55(19):8464-76
115. Sabnis G, Goloubeva O, Jelovac D, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007;13(9):2751-7
116. Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 2013;288(18):12932-43
117. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96(9):1241
118. Bedoya DJ, Mitsiades N. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. Onco Targets Ther 2013;6:9-18
119. de Vore NM, Scott EE. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 2012;482(7383):116
120. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009;10(10):981
121. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8(10):794-805
122. Guo AM, Arbab AS, Falck JR, et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20- hydroxyeicosatetraenoic acidinduced endothelial cell proliferation. J Pharmacol Exp Ther 2007;321(1):18-27
123. Ljubimov AV, Grant MB. P450 in the angiogenesis affair: the unusual suspect. Am J Pathol 2005;166(2):341-4
124. Jiang M, Mezentsev A, Kemp R, et al. Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 2004;94(2):167-74
125. Panigrahy D, Kaipainen A, Greene ER, et al. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 2010;29(4):723-35
126. Preissner S, Dunkel M, Hoffmann MF, et al. Drug cocktail optimization in chemotherapy of cancer. PLoS One 2012;7(12):e51020
127. Narayan ARH, Sherman DH. Re-engineering nature's catalysts. Science 2013;339(6117):283-4
128. Landwehr M, Hochrein L, Otey CR, et al. Enantioselective alphahydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J Am Chem Soc 2006;128(18):6058-9
129. Bistolas N, Wollenberger U, Jung C, et al. Cytochrome P450 biosensors-a review. Biosens Bioelectron 2005;20(12):2408-23
130. Caswell JM, O'Neill M, Taylor SJ, Moody TS. Engineering and application of P450 monooxygenases in pharmaceutical and metabolite synthesis. Curr Opin Chem Biol 2013;17(2):271-5
131. Dietrich JA, Yoshikuni Y, Fisher KJ, et al. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3). ACS Chem Biol 2009;4(4):261-7
132. Sakaki T. Practical application of cytochrome P450. Biol Pharm Bull 2012;35(6):844-49
133. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29(6):726-76
134. 3 target genes. Mol Endocrinol 2005;19(11):2685-95
135. Singh D, Kashyap A, Pandey RV, et al. Novel advances in cytochrome P450 research. Drug Discov Today 2011;16(17-18):793-9